Currently, multiple ALK fusion partners have been identified, of which echinoderm microtubule-associated protein-like 4 (EML4) is the most frequent, with nine variants occurring in nearly 80% of all the ALK fusion cases of non-small cell lung cancer (NSCLC) (6–8). The gene discussed is ALK; the disease is non-small cell lung carcinoma.